1 / 9

CAPRIE: Clopidogrel versus Aspirin in Patients at risk of Ischemic Events

CAPRIE: Clopidogrel versus Aspirin in Patients at risk of Ischemic Events. Purpose To assess the relative efficacy of the antiplatelet drugs clopidogrel and aspirin in reducing the risk of thrombotic events in patients with atherosclerotic disease. Reference

jocelyn-zimmerman
Download Presentation

CAPRIE: Clopidogrel versus Aspirin in Patients at risk of Ischemic Events

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. CAPRIE: Clopidogrel versus Aspirin in Patients at risk of Ischemic Events Purpose To assess the relative efficacy of the antiplatelet drugs clopidogrel and aspirin in reducing the risk of thrombotic events in patients with atherosclerotic disease. Reference CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329–39.

  2. CAPRIE: Clopidogrel versus Aspirin in Patients at risk of Ischemic Events- TRIAL DESIGN - Design Multicenter, multinational, randomized, double-blind, parallel group Patients 19,185 patients with atherosclerotic vascular disease (either recent ischemic stroke, recent MI or symptomatic peripheral arterial disease) Follow up and primary endpoint Primary combined endpoint: ischemic stroke, MI or vascular death. Mean 1.9 years follow up. Treatment Aspirin 325 mg once daily or clopidogrel 75 mg once daily

  3. CAPRIE: Clopidogrel versus Aspirin in Patients at risk of Ischemic Events- TRIAL DESIGN continued- Patient subgroups Clopidogrel (n=9599) Aspirin (n=9586) Stroke 33.4% 33.7% MI 32.9% 32.7% Peripheral arterial disease 33.7% 33.6% CAPRIE Steering Committee. Lancet 1996; 348 :1329–39.

  4. CAPRIE: Clopidogrel versus Aspirin in Patients at risk of Ischemic Events- RESULTS - • Annual event rate for primary endpoint of ischemic stroke, MI or vascular death significantly reduced in clopidogrel group compared with aspirin (5.32 vs. 5.83%, p<0.043) • Effect of clopidogrel compared with aspirin indicated that benefit may not be identical between subgroups (p=0.042 for test of heterogeneity): • reduction in event rate was significant in patients with existing peripheral arterial disease • reduction in the group with previous stroke, though not significant • increased event rate in the group with previous MI, though not significant • Clopidogrel was well tolerated as defined by withdrawal rate from trial: only marginally higher vs aspirin (21.3 vs. 21.1%)

  5. Aspirin Clopidogrel CAPRIE: Clopidogrel versus Aspirin in Patients at risk of Ischemic Events- RESULTS continued - Primary endpoint: stroke, MI or vascular death Cumulative 20 risk (%) 15 10 5 p=0.043 0 0 6 12 18 24 30 36 Months after randomization CAPRIE Steering Committee. Lancet 1996; 348 :1329–39.

  6. Treatment group (patient years at risk) Events per year (%) Relative risk reduction (95% CI) Subgroup p CAPRIE: Clopidogrel versus Aspirin in Patients at risk of Ischemic Events- RESULTS continued - Primary endpoint by subgroup Relative risk reduction (%) Aspirin better Clopidogrel better 7.15 7.3% 0.26 Clopidogrel (6054) Stroke 7.71 (–5.7 to 18.7) Aspirin (5979) 5.03 –3.7% 0.66 Clopidogrel (5787) MI 4.84 (–22.1 to 12.0) Aspirin (5843) Peripheral arterial disease 3.71 23.8% 0.0028 Clopidogrel (5795) 4.86 (8.9 to 36.2) Aspirin (5797) 5.32 8.7% 0.043 Clopidogrel (17,636) All patients 5.83 (0.3 to 16.5) Aspirin (17,519) –30 –20 –10 0 10 20 30 40 CAPRIE Steering Committee. Lancet 1996; 348 :1329–39.

  7. CAPRIE: Clopidogrel versus Aspirin in Patients at risk of Ischemic Events- RESULTS continued- Stroke and MI Aspirin Clopidogrel Patient years at risk 17,519 17,636 Stroke Nonfatal 430 405 Fatal 32 33 MI Nonfatal 270 226 Fatal 63 49 CAPRIE Steering Committee. Lancet 1996; 348 :1329–39.

  8. CAPRIE: Clopidogrel versus Aspirin in Patients at risk of Ischemic Events- SUMMARY - Compared with aspirin, in patients with atherosclerotic vascular disease, clopidogrel: • Reduced the primary combined endpoint of stroke, MI or vascular death in the total study population • Conferred benefit in peripheral arterial disease and stroke subgroups • Conferred no significant benefit in previous MI subgroup

  9. CAPRIE: Clopidogrel versus Aspirin in Patients at risk of Ischemic Events- SUMMARY - Compared with aspirin, in patients with atherosclerotic vascular disease, clopidogrel: • Reduced the primary combined endpoint of stroke, MI or vascular death in the total study population • Conferred benefit in peripheral arterial disease subgroup • Conferred no significant change in risk in stroke and MI subgroups

More Related